Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

PRINCETON, N.J., Feb. 7, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended December 31, 2010.

Financial ResultsRevenues were $0.2 million during the quarter ended December 31, 2010 compared to $0.3 million for the quarter ended December 31, 2009 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended December 31, 2010 was $24.0 million. Pharmasset held $102.7 million in cash and cash equivalents as of December 31, 2010. On January 26, 2011, we completed a common stock offering raising an additional $123.4 million.

Total operating expenses for the quarter ended December 31, 2010 were $23.8 million as compared to $13.4 million for the same period in 2009. The increase in operating expenses for the quarter ended December 31, 2010 was primarily the result of preclinical and clinical trial costs for PSI-7977 and PSI-938 of which $5.9 million was related to API manufacturing (and related drug supply) costs and pegylated interferon and ribavirin costs for the studies of PSI-7977 and PSI-938.

Pharmasset reported a net loss of $23.5 million, or $0.69 per share, for the quarter ended December 31, 2010, as compared to a net loss of $13.9 million, or $0.49 per share, for the quarter ended December 31, 2009.

Recent Operational Highlights:-- Presented final Phase 2a results with PSI-7977 at the American Association for the Study of Liver Diseases (AASLD) in October 2010

-- Initiated Part 2 of a Phase 1 study that includes combinations of PSI-7977 and PSI-938

-- Roche reported 12 week interim results from the PROPEL study at AASLD 2010

-- Initiated the exploratory interferon sparing ELECTRON trial with PSI-7977 in genotype 2 or 3 HCV infected patients

-- Reported positive 12 week safety and efficacy results from the PROTON trial in genotype 2 or 3 patients

-- Reported 7 and 14 day monotherapy results with PSI-938

-- Announced a clinical collaboration with Bristol-Myers Squibb to investigate the combination of PSI-7977 and BMY-790052 in genotype 1, 2 or 3 treatment naïve HCV patients.

-- Completed a common stock offering raising $123.4 million in net proceeds.

"We continue to make good progress with all of our nucleotide analog programs for HCV," stated Schaefer Price, President and Chief Executive Officer. "We have maintained the momentum of 2010 into 2011 by initiating the interferon sparing ELECTRON trial, as well as a 7977 and 938 combination trial. As we look to better define the role of nucleotide analogs in the future treatment of HCV, we and our partners are planning three interferon-free studies in the first half of 2011, including our own proprietary nucleotide analog combination trial with 7977 and 938. While other DAA combination trials have been impacted by the development of resistance, our nucleotide analog trials continue to demonstrate good antiviral activity, safety and a high barrier to resistance."

Calendar Year 2011 Anticipated Milestones:-- Pharmasset expects to report SVR12 data from its ongoing Phase 2b PROTON trial with PSI-7977 in HCV genotype 2/3 patients in the second quarter of 2011

-- Pharmasset expects to report the 12 week interim analysis from its PROTON trial genotype 1 arms in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2b trial exploring up to 24 week durations of PSI-7977 and pegylated interferon and ribavirin in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2 combination study with PSI-7977 and PSI-938 in mid-2011

-- Bristol-Myers Squibb is anticipated to initiate a combination trial of PSI-7977 and BMY-790052 during the first half of 2011

-- Pharmasset plans to submit an IND for PSI-661 in the first quarter of 2011 and to initiate a phase 1 trial in the second quarter of 2011

-- Roche expects to initiate INFORM-SVR with RG7128 and RG7227 in the first quarter of 2011

-- Roche expects to initiate a Phase 2 study with RG7128 in HCV genotype 2/3 patients in the first half of 2011

-- Roche expects to initiate a Phase 3 program with RG7128 in 2011 and file in 2013

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated dosing in two Phase 2b studies in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and has recently initiated a 14-day combination study with PSI-7977. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 613-4181 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.

PHARMASSET, INC.CONDENSED STATEMENTS OF OPERATIONS(UNAUDITED)(in thousands, except share and per share amounts)Three Months EndedDecember 31,20102009Revenues

$
247$
269COSTS AND EXPENSES:  Research and development

18,7689,197  General and administrative

5,0764,239Total costs and expenses

23,84413,436Operating loss

(23,597)(13,167)Investment income

34Other income

489-Interest expense

(398)(706)Loss before income taxes

(23,503)(13,869)Provision for income taxes

--Net loss

$
(23,503)$
(13,869)Net loss per share: basic and diluted

$
(0.69)$
(0.49)Weighed average shares outstanding:basic and diluted

34,106,89028,287,609PHARMASSET, INC.BALANCE SHEETS(in thousands, except par value, share and per share amounts)As ofAs ofDecember 31,September 30,20102010(unaudited)ASSETSCURRENT ASSETS:  Cash and cash equivalents

$
2,651

$
27,081  Amounts due from collaboration partner

6

6  Prepaid expenses and other assets

702

718Total current assets

103,359

127,805EQUIPMENT AND LEASEHOLD IMPROVEMENTS:  Equipment

4,098

4,060  Leasehold improvements

1,837

1,8375,935

5,897  Less accumulated depreciation and amortization

(4,327)

(4,184)Total equipment and leasehold improvements, net

1,608

1,713Restricted cash

100

100Other assets

141

143Total

$
5,208

$
29,761LIABILITIES AND STOCKHOLDERS’ EQUITYCURRENT LIABILITIES:  Current portion of long-term debt

$
7,796

$
8,705  Accounts payable

3,687

5,037  Accrued expenses

4,554

5,863  Deferred rent

25

25  Deferred revenue

985

985Total current liabilities

17,047

20,615  Deferred rent

86

93  Deferred revenue

1,724

1,971  Long-term debt, net of discount of $97 and $150 as of
December 31, 2010 and September 30, 2010, respectively

1,515

2,934Total liabilities

20,372

25,613Commitments and contingenciesSTOCKHOLDERS' EQUITY:  Common stock, $0.001 par value, 100,000,000 shares authorized,
34,220,379 and 34,043,898 shares issued and outstanding at
December 31, 2010 and September 30, 2010, respectively

34

34  Warrants to purchase 63,623 shares of common stock for
$12.05 per share at December
31, 2010, and 127,248
shares of common stock for $12.05 per share at
September 30, 2010

640

1,230  Additional paid-in capital

341,132

336,351  Accumulated deficit

(256,970)

(233,467)Total stockholders’ equity

84,836

104,148Total

$
5,208

$
29,761
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):